In GCA, why might you target GM-CSF over IL-6? Entirely plausible TCZ might be leaving some Th1 stones unturned, esp: vascular remodelling downreg pathways Transcriptomics from toci/mavri-treated TAB show it's plausible beyond just theory... Cid group #ACR21 ABST0506 @RheumNow https://t.co/YephlzHOdj

Do you use ANCA to change Rx in prevalent GPA pts? GS401 #ACR21 @RheumNow

Dr De Miguel on subclinical large vessel vasculitis in PMR. US assessment. 22% had subclinical GCA. 90% LVV, 10% cranial GCA. Abstr#0466 #ACR21 @RheumNow https://t.co/PDCynMAigi

Our latest article on outcomes of patients with vasculitis and PMR and COVID-19 published in @TheLancetRheum . @rheum_covid project with co-leads @SattuiSEMD and @EBRheum . https://t.co/8NTAafdYRA

• https://www.sciencedirect.com/science/article/pii/S2665991321003167

📌Pre-Test Probability in GCA ESR/CRP can be normal: ~10% of pts at diagnosis -20-40% at time or relapse #ACR21 #ACRAmbassador #RheumTwitter https://t.co/kenaD31pYa

Dr Doliner @zach_wallace_md on ILD in AAV. ILD in 13% - of which 76% fibrotic. UIP most common. Most MPO+, but also rarely seen with PR3+. 47% ⬆️ risk of death. Abstr#0430 #ACR21 @RheumNow https://t.co/6MnxqW92bz

Dr O'Brien on co-existent AAV and RA. Not something I'm used to seeing, but maybe we need to think about it more? 25 cases with RA+AAV, 52 with RA + ANCA but no AAV, not sure what the denominator is here though. Abstr#0428 #ACR21 @RheumNow @profgayecunnane https://t.co/fN3BRpc7UJ

How much ritux for AAV maintenance? Ever since we started using it, no-one's been sure. If absolute B cell depletion is your goal, @VUMCRheum data suggest >3.3mg/d is safest for that 500mg q6m = 2.7 mg/d 500mg q4m = 4.1 mg/d 1000mg q6m = 5.5mg/d #ACR21 ABST0416 @RheumNow https://t.co/mYAgKhHT7j